Buy Bulk IGF-DES 1,3 1mg (Save Up to 41%)

IGF-DES 1,3 (1mg) is a synthetic analog of insulin-like growth factor 1 (IGF-I) that has been the subject of extensive animal and in vitro studies in recent years. IGF-I is a peptide hormone that plays a key role in the regulation of cell growth, differentiation, and metabolism, and it has been implicated in a wide range of physiological processes, including tissue repair, bone growth, and muscle development.

The development of IGF-DES 1,3 was driven by the need to overcome some of the limitations of native IGF-I, such as its short half-life and poor tissue penetration. IGF-DES 1,3 is a truncated form of IGF-I that lacks the first three amino acids of the native sequence, and it has been shown to have a longer half-life and greater tissue penetration than native IGF-I.¹

In vitro studies have provided evidence that IGF-DES 1,3 is 10 times more effective than IGF-I in stimulating hypertrophy and proliferation of cultured cells.¹ In vivo studies conducted in mice have corroborated these findings, showing that administering a lower dose of IGF-DES 1,3 resulted in a significant increase in kidney and heart weights compared to control mice. In contrast, a higher dose of IGF-I was required to produce a similar effect.²

Another study conducted in rats revealed that IGF-DES 1,3 may be useful in overcoming growth impairment in renal failure. In that study, the des(1-3) variant of IGF-I was compared with native IGF-I in its growth-promoting effects in rats following partial nephrectomy. The study involved three groups of rats treated with IGF-I, IGF-DES 1,3, or vehicle. The results indicated that the food intake and nitrogen balance of the peptide-treated groups improved compared to the vehicle-treated nephrectomized group. However, IGF-DES 1,3 was found to be more effective in reducing nitrogen excretion and muscle protein degradation and decreasing serum urea levels.³

While the results of animal and in vitro studies of IGF-DES 1,3 are promising, more research is needed to fully understand its potential therapeutic uses and potential side effects. In conclusion, IGF-DES 1,3 is a synthetic analog of IGF-I that has shown promising results in animal and in vitro studies. Its longer half-life and greater tissue penetration make it a potentially valuable therapeutic agent for a variety of conditions, and ongoing clinical trials will provide more information about its safety and efficacy in humans.

References: 1. Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996 Oct;28(10):1085-7. 2. Gillespie C, Read LC, Bagley CJ, Ballard FJ. Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice. J Endocrinol. 1990 Dec;127(3):401-5. 3. Martin AA, Tomas FM, Ballard FJ, Read LC. Insulin-like growth factor I and its variant, des(1-3)IGF-I, improve nitrogen balance and food utilization in rats with renal failure. Miner Electrolyte Metab. 1992;18(2-5):264-8. 4.